600276 恒瑞医药
已收盘 06-18 15:00:00
资讯
新帖
简况
施罗德增持恒瑞医药(01276)94.88万股 每股作价约54.54港元
智通财经 · 06-17
施罗德增持恒瑞医药(01276)94.88万股 每股作价约54.54港元
恒瑞医药(01276)6月17日斥资约562.45万元回购12万股A股
智通财经 · 06-17
恒瑞医药(01276)6月17日斥资约562.45万元回购12万股A股
恒瑞医药获NMPA批准 达匹昔利布伊塞酸盐片新适应症 CDK4/6抑制剂再获认可
美股速递 · 06-16
恒瑞医药获NMPA批准 达匹昔利布伊塞酸盐片新适应症 CDK4/6抑制剂再获认可
恒瑞医药：HRS-7525片获临床试验批准
南方财经网 · 06-16
恒瑞医药：HRS-7525片获临床试验批准
2026 EULAR︱恒瑞医药IFNAR1/TACI抗体融合蛋白SHR-2173治疗系统性红斑狼疮I期研究结果精彩亮相
恒瑞医药官微 · 06-11
2026 EULAR︱恒瑞医药IFNAR1/TACI抗体融合蛋白SHR-2173治疗系统性红斑狼疮I期研究结果精彩亮相
恒瑞医药三款新药获批临床，创新研发再添新进展｜医药早参
每日经济新闻 · 06-11
恒瑞医药三款新药获批临床，创新研发再添新进展｜医药早参
恒瑞医药(01276)6月10日斥资46.04万元回购1万股A股
智通财经 · 06-10
恒瑞医药(01276)6月10日斥资46.04万元回购1万股A股
恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%
证券日报 · 06-09
恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%
恒瑞医药及子公司三款药物获批临床
财中社 · 06-09
恒瑞医药及子公司三款药物获批临床
恒瑞医药(01276)6月9日斥资319.36万元回购7万股A股
智通财经 · 06-09
恒瑞医药(01276)6月9日斥资319.36万元回购7万股A股
恒瑞医药(01276)6月8日斥资2042.57万元回购44.4万股A股
智通财经 · 06-08
恒瑞医药(01276)6月8日斥资2042.57万元回购44.4万股A股
港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会
智通财经 · 06-05
港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会
恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股
智通财经 · 06-04
恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股
美团、京东、阿里、腾讯，集体下跌
第一财经 · 06-03
美团、京东、阿里、腾讯，集体下跌
恒瑞医药(01276)：截至5月末公司累计回购A股股份1205.62万股
智通财经 · 06-02
恒瑞医药(01276)：截至5月末公司累计回购A股股份1205.62万股
恒瑞医药累计回购1206万股 金额7.72亿元
财中社 · 06-02
恒瑞医药累计回购1206万股 金额7.72亿元
恒瑞医药：公司坚持科技创新与国际化发展战略，致力于发展好主营业务
证券日报 · 06-01
恒瑞医药：公司坚持科技创新与国际化发展战略，致力于发展好主营业务
恒瑞医药：公司将继续大力推进“科技创新”和“国际化”两大发展战略
证券日报 · 05-29
恒瑞医药：公司将继续大力推进“科技创新”和“国际化”两大发展战略
恒瑞医药：公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束
证券日报 · 05-29
恒瑞医药：公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束
恒瑞医药：公司目前已在中国获批上市25款1类创新药、5款2类新药
证券日报 · 05-29
恒瑞医药：公司目前已在中国获批上市25款1类创新药、5款2类新药
暂无数据
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":48.42,"timestamp":1781766000000,"preClose":46.99,"halted":0,"volume":118592836,"delay":0,"changeRate":0.0304,"floatShares":6379000000,"shares":6637000000,"eps":1.2233,"marketStatus":"已收盘","change":1.43,"latestTime":"06-18 15:00:00","open":46.99,"high":49.5,"low":46.61,"amount":5748000000,"amplitude":0.0615,"askPrice":48.42,"askSize":1440,"bidPrice":48.41,"bidSize":1782,"shortable":0,"etf":0,"ttmEps":1.2233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":5,"adr":0,"adjPreClose":46.99,"symbolType":"stock","openAndCloseTimeList":[[1781746200000,1781753400000],[1781758800000,1781766000000]],"highLimit":51.69,"lowLimit":42.29,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":5.05,"roa":"--","peRate":39.58146,"roe":"4.15%","epsLYR":1.19,"committee":0.39238,"marketValue":321373000000,"turnoverRate":0.0186,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-22。","hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":54.65,"timestamp":1781770088004,"preClose":53,"halted":0,"volume":6247377,"delay":0,"premium":"-2.25"},"floatMarketCap":308871000000},"requestUrl":"/m/hq/s/600276/tweets","defaultTab":"tweets","newsList":[{"id":"2644745377","title":"施罗德增持恒瑞医药(01276)94.88万股 每股作价约54.54港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644745377?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:43","pubTimestamp":1781696627,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，6月12日，施罗德增持恒瑞医药(01276)94.88万股，每股作价54.5391港元，总金额约为5174.67万港元。增持后最新持股数目约为1320.22万股，持股比例为5.11%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1655091616.SGD","LU2097828557.USD","LU0405327494.USD","BK0188","LU2580892789.USD","BK0060","LU1997244956.HKD","LU2580892862.HKD","BK0183","LU2543165471.USD","LU1064130708.USD","LU1781817850.SGD","LU1820825898.SGD","BK0239","LU2148510915.USD","LU2097828714.EUR","BK0196","LU0405327148.USD","LU1328615791.USD","LU1580142542.USD","600276","01276","LU1255011170.USD","LU1146622755.USD","LU2097828631.EUR","LU2488822045.USD","LU2097828805.USD","LU2495084118.USD","LU1969619763.USD","LU0359201612.USD","BK1191","LU1064131003.USD","BK0028","EWH","LU1023057109.AUD","LU1997245177.USD","LU0359202008.SGD","LU2289578879.USD","LU2328871848.SGD","LU0359201885.HKD","LU1997245094.SGD","LU2097828474.EUR","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644714982","title":"恒瑞医药(01276)6月17日斥资约562.45万元回购12万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644714982","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644714982?lang=zh_cn&edition=full","pubTime":"2026-06-17 16:56","pubTimestamp":1781686567,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月17日该公司斥资约人民币562.45万元回购12万股A股，回购价格为每股人民币46.85至46.88元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1655091616.SGD","LU1064131003.USD","159982","LU0405327494.USD","LU1997244956.HKD","LU2289578879.USD","LU1781817850.SGD","LU1820825898.SGD","LU1997245177.USD","LU2580892789.USD","01276","LU2097828631.EUR","BK0183","LU1328615791.USD","LU0359201885.HKD","LU1146622755.USD","LU2580892862.HKD","LU2097828714.EUR","BK1191","LU1969619763.USD","LU1997245094.SGD","LU1580142542.USD","BK0188","LU2495084118.USD","LU2328871848.SGD","399300","LU0359201612.USD","LU0359202008.SGD","LU1255011170.USD","LU2097828557.USD","LU2543165471.USD","BK0196","LU1064130708.USD","LU2097828805.USD","BK0028","LU2097828474.EUR","BK0060","LU2148510915.USD","600276","BK0239","LU2488822045.USD","BK0012","LU0405327148.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184570619","title":"恒瑞医药获NMPA批准 达匹昔利布伊塞酸盐片新适应症 CDK4/6抑制剂再获认可","url":"https://stock-news.laohu8.com/highlight/detail?id=1184570619","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184570619?lang=zh_cn&edition=full","pubTime":"2026-06-16 21:33","pubTimestamp":1781616795,"startTime":"0","endTime":"0","summary":"恒瑞医药宣布，其创新药物达匹昔利布伊塞酸盐片（一种CDK4/6抑制剂）已收到国家药品监督管理局（NMPA）关于新适应症的批准通知。这一进展标志着该药物在临床应用范围上的进一步拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","600276","LU1064130708.USD","LU2328871848.SGD","LU1064131003.USD","LU0359202008.SGD","LU0405327494.USD","LU2543165471.USD","LU1655091616.SGD","LU1997244956.HKD","LU2495084118.USD","LU1580142542.USD","BK0196","LU2097828557.USD","LU2097828714.EUR","LU1146622755.USD","LU1328615791.USD","LU2148510915.USD","BK0183","BK0239","BK0028","LU0359201612.USD","LU2580892789.USD","LU1820825898.SGD","BK0188","LU1255011170.USD","BK1191","LU2097828474.EUR","BK0060","BK0012","LU2289578879.USD","LU1969619763.USD","LU1023057109.AUD","LU0359201885.HKD","LU2488822045.USD","01276","LU0405327148.USD","LU1997245094.SGD","LU1781817850.SGD","LU2097828805.USD","LU1997245177.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643730703","title":"恒瑞医药：HRS-7525片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2643730703","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643730703?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:03","pubTimestamp":1781600580,"startTime":"0","endTime":"0","summary":"南财智讯6月16日电，恒瑞医药公告，HRS-7525片收到国家药品监督管理局签发的《药物临床试验批准通知书》，审批结论为同意该药单药在晚期实体瘤中开展临床试验；受理号为CXHL2600319、CXHL2600320，申请事项为临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606163773104428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU2097828474.EUR","LU1997244956.HKD","LU1064130708.USD","BK0183","LU2495084118.USD","LU1255011170.USD","BK0028","LU2097828805.USD","LU0405327148.USD","BK0012","LU0405327494.USD","LU1146622755.USD","LU1820825898.SGD","LU2580892862.HKD","LU1997245177.USD","LU2543165471.USD","LU2289578879.USD","BK0188","LU2097828631.EUR","LU1969619763.USD","LU2148510915.USD","LU0359201612.USD","LU1655091616.SGD","LU2097828557.USD","LU2328871848.SGD","01276","LU1064131003.USD","LU1580142542.USD","BK0060","600276","LU0359202008.SGD","LU1328615791.USD","BK1191","LU1781817850.SGD","LU1997245094.SGD","LU2097828714.EUR","LU2580892789.USD","LU2488822045.USD","LU1023057109.AUD","LU0359201885.HKD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642118285","title":"2026 EULAR︱恒瑞医药IFNAR1/TACI抗体融合蛋白SHR-2173治疗系统性红斑狼疮I期研究结果精彩亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2642118285","media":"恒瑞医药官微","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642118285?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:12","pubTimestamp":1781172720,"startTime":"0","endTime":"0","summary":"2026年欧洲抗风湿病联盟年会已于当地时间6月3日至6日在英国伦敦隆重召开。期间，恒瑞医药自主研发的IFNAR1/TACI抗体融合蛋白SHR-2173用于系统性红斑狼疮的一项多中心、开放标签、多剂量递增I期临床研究成果精彩亮相1。目前，针对上述任一通路的单靶点治疗均难以实现整体病情的有效控制。各组均无导致试验终止的TEAE。本研究的初步临床证据为SHR-2173的持续开发提供了重要依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-11/doc-iniaztwk5483464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2580892862.HKD","LU1328615791.USD","LU2289578879.USD","600276","LU2543165471.USD","LU1997244956.HKD","01276","LU2488822045.USD","LU1820825898.SGD","LU2328871848.SGD","BK0060","BK0183","BK0188","LU0359202008.SGD","LU1064131003.USD","LU1146622755.USD","LU1655091616.SGD","LU2097828557.USD","LU0405327494.USD","BK1191","LU2097828714.EUR","LU1969619763.USD","LU1255011170.USD","LU0359201612.USD","LU1023057109.AUD","LU1064130708.USD","BK0196","LU1997245094.SGD","LU2097828631.EUR","TACI","LU0405327148.USD","LU0359201885.HKD","BK0028","LU2495084118.USD","LU2148510915.USD","BK0239","LU2097828805.USD","LU1781817850.SGD","LU1997245177.USD","LU2097828474.EUR","BK0012","LU1580142542.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642470626","title":"恒瑞医药三款新药获批临床，创新研发再添新进展｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2642470626","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642470626?lang=zh_cn&edition=full","pubTime":"2026-06-11 09:31","pubTimestamp":1781141460,"startTime":"0","endTime":"0","summary":"截至6月10日收盘，市场全天震荡调整，沪深两市成交额2.62万亿元。医药ETF（512120）上涨1.53%，港股通生物科技ETF（159102）上涨1.40%。相关个股中，恒瑞医药上涨1.36%、药明康德上涨3.81%、片仔癀上涨0.46%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606113767626750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606113767626750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2543165471.USD","BK0188","LU0405327148.USD","BK1574","01276","LU1820825898.SGD","LU2097828805.USD","LU2148510915.USD","BK0239","BK0012","LU2580892862.HKD","LU1064130708.USD","600276","LU2328871848.SGD","LU2097828557.USD","LU2580892789.USD","LU2488822045.USD","BK0196","BK0060","LU1580142542.USD","LU1969619763.USD","LU1146622755.USD","LU2097828474.EUR","BK1191","BK1515","LU1064131003.USD","LU1328615791.USD","BK0183","LU1997245094.SGD","LU2495084118.USD","LU1655091616.SGD","LU1997245177.USD","LU2289578879.USD","LU0405327494.USD","LU2097828631.EUR","BK0028","LU0359202008.SGD","LU1023057109.AUD","LU1781817850.SGD","BK1161","LU1255011170.USD","LU1997244956.HKD","LU0359201612.USD","09939","159938","LU0359201885.HKD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442317","title":"恒瑞医药(01276)6月10日斥资46.04万元回购1万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442317","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642442317?lang=zh_cn&edition=full","pubTime":"2026-06-10 17:29","pubTimestamp":1781083796,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月10日，该公司斥资46.04万元回购1万股A股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159982","LU0359201885.HKD","LU1781817850.SGD","LU1969619763.USD","399300","LU1997245177.USD","01276","BK0239","LU2495084118.USD","LU1255011170.USD","LU0405327494.USD","LU1580142542.USD","LU1820825898.SGD","LU2488822045.USD","LU0405327148.USD","LU1146622755.USD","LU0359201612.USD","LU1023057109.AUD","LU1328615791.USD","LU2328871848.SGD","LU1064131003.USD","LU1064130708.USD","LU2289578879.USD","BK1191","LU2543165471.USD","LU0359202008.SGD","LU2580892862.HKD","BK0028","BK0196","LU1655091616.SGD","LU2097828474.EUR","BK0183","LU2097828631.EUR","LU1997245094.SGD","LU2097828714.EUR","LU2097828805.USD","LU1997244956.HKD","LU2148510915.USD","600276","BK0188","BK0012","LU2580892789.USD","BK0060","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642679744","title":"恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642679744","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642679744?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:54","pubTimestamp":1781006040,"startTime":"0","endTime":"0","summary":"证券日报网讯6月9日，恒瑞医药在互动平台回答投资者提问时表示，公司始终高度重视全体股东利益，致力于发展好主营业务，以扎实的经营基本面维护公司长期价值，从而以更好的发展回馈股东。（1）公司经营业绩稳步提升，整体发展态势持续向好。2025年全年，公司实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765312960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642466820","title":"恒瑞医药及子公司三款药物获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2642466820","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642466820?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:25","pubTimestamp":1780997100,"startTime":"0","endTime":"0","summary":"6月9日，恒瑞医药（600276/01276）发布公告，公司及子公司山东盛迪医药有限公司、广东恒瑞医药有限公司近日收到HRS-6209胶囊、HRS-8080片、HRS-9813胶囊的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765192426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","LU2580892862.HKD","LU1997245094.SGD","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","LU2328871848.SGD","BK0188","LU2097828714.EUR","BK0183","LU1997244956.HKD","01276","LU0359201612.USD","LU1997245177.USD","BK1191","LU2097828631.EUR","LU2488822045.USD","BK0239","LU1064131003.USD","LU2580892789.USD","LU1969619763.USD","LU0405327148.USD","BK0028","LU2097828557.USD","LU1580142542.USD","LU1781817850.SGD","LU2097828805.USD","LU1064130708.USD","LU2289578879.USD","LU1255011170.USD","LU2495084118.USD","BK0196","600276","LU1655091616.SGD","BK0060","LU1023057109.AUD","BK0012","LU1820825898.SGD","LU2097828474.EUR","LU0405327494.USD","LU2148510915.USD","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642146314","title":"恒瑞医药(01276)6月9日斥资319.36万元回购7万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642146314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642146314?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:49","pubTimestamp":1780994962,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月9日，该公司斥资人民币319.36万元回购7万股A股股份，每股回购价人民币45.3-45.82元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997244956.HKD","01276","BK0012","BK0196","LU0405327494.USD","LU1655091616.SGD","BK0239","LU0359201612.USD","LU1255011170.USD","LU2289578879.USD","LU1820825898.SGD","LU1781817850.SGD","LU2580892789.USD","LU1023057109.AUD","LU0359201885.HKD","LU0405327148.USD","159982","LU1997245094.SGD","LU1580142542.USD","BK0028","BK0183","LU1064130708.USD","399300","LU2328871848.SGD","LU2580892862.HKD","LU2097828474.EUR","LU1997245177.USD","LU2543165471.USD","LU0359202008.SGD","LU1064131003.USD","LU1969619763.USD","BK0060","LU1146622755.USD","LU2495084118.USD","BK0188","LU1328615791.USD","LU2097828557.USD","BK1191","LU2148510915.USD","LU2097828631.EUR","LU2097828714.EUR","LU2488822045.USD","LU2097828805.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641029491","title":"恒瑞医药(01276)6月8日斥资2042.57万元回购44.4万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641029491","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641029491?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:21","pubTimestamp":1780906880,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月8日，该公司斥资2042.57万元回购44.4万股A股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1146622755.USD","LU0405327494.USD","BK0239","BK0060","BK0188","LU1969619763.USD","LU1580142542.USD","BK0028","600276","LU1064130708.USD","LU2097828474.EUR","LU1255011170.USD","399300","BK0012","LU2148510915.USD","LU0359202008.SGD","LU2328871848.SGD","LU1997245094.SGD","BK1191","LU1655091616.SGD","LU2097828557.USD","LU2097828714.EUR","LU1997244956.HKD","LU2097828631.EUR","01276","LU1781817850.SGD","LU1820825898.SGD","LU1997245177.USD","LU2097828805.USD","LU2289578879.USD","LU1023057109.AUD","BK0183","LU2495084118.USD","LU1328615791.USD","LU2488822045.USD","LU2580892789.USD","LU0359201612.USD","LU0359201885.HKD","LU2543165471.USD","LU0405327148.USD","LU2580892862.HKD","159982","LU1064131003.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641619989","title":"港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641619989","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641619989?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:55","pubTimestamp":1780624500,"startTime":"0","endTime":"0","summary":"消息面上，据恒瑞医药官微消息，近日，在ASCO 2026年会上，公司创新药“双艾”组合联合经动脉化疗栓塞术对比单纯TACE治疗不可切除肝细胞癌的全国多中心、随机对照、III期研究亮相口头报告环节。该研究为这一“TACE联合靶免”治疗策略在uHCC中的应用提供了有力的循证支持。基于该研究，“双艾”组合联合TACE治疗不可切除的肝细胞癌的上市许可申请已于2026年年初获国家药监局受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828631.EUR","600276","LU1064130708.USD","LU2328871848.SGD","LU1064131003.USD","LU0359202008.SGD","LU0405327494.USD","LU2543165471.USD","LU1655091616.SGD","LU1997244956.HKD","LU2495084118.USD","LU1580142542.USD","BK0196","LU2097828557.USD","BK4585","LU2097828714.EUR","LU1146622755.USD","LU1328615791.USD","LU2148510915.USD","BK0183","BK0239","BK0028","LU0359201612.USD","TACE","LU2580892789.USD","LU1820825898.SGD","BK0188","VXUS","LU1255011170.USD","BK1191","LU2097828474.EUR","BK4588","BK0060","BK0012","LU2289578879.USD","LU1969619763.USD","LU1023057109.AUD","LU0359201885.HKD","LU2488822045.USD","01276","LU0405327148.USD","LU1997245094.SGD","LU1781817850.SGD","LU2097828805.USD","LU1997245177.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155910","title":"恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155910","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640155910?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:18","pubTimestamp":1780564719,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月4日，该公司斥资人民币1982.37万元回购42万股A股股份，每股回购价人民币46.7-47.7元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600276","LU2580892862.HKD","LU1997245094.SGD","01276","LU1781817850.SGD","LU1146622755.USD","LU0405327494.USD","LU2488822045.USD","LU0359201885.HKD","LU2495084118.USD","LU0359202008.SGD","LU2097828714.EUR","BK0188","LU1655091616.SGD","LU1969619763.USD","LU1997245177.USD","LU0405327148.USD","LU2328871848.SGD","BK0183","399300","LU1023057109.AUD","LU2148510915.USD","LU2097828474.EUR","159982","LU1328615791.USD","LU1997244956.HKD","LU2097828805.USD","LU2580892789.USD","BK0028","LU1820825898.SGD","BK1191","LU2289578879.USD","LU1580142542.USD","LU0359201612.USD","LU2097828557.USD","LU1064131003.USD","LU1064130708.USD","LU2097828631.EUR","BK0012","BK0196","LU2543165471.USD","BK0060","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640977122","title":"美团、京东、阿里、腾讯，集体下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640977122","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640977122?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:32","pubTimestamp":1780475520,"startTime":"0","endTime":"0","summary":"6月3日，香港恒生指数收跌1.56%，恒生科技指数跌2.74%。\n\n 科网股普跌，金蝶国际跌超7%，美团跌近6%，京东集团跌超4%，腾讯控股、阿里巴巴跌超3%。\n\n 生物医药板块下挫，药明生物、药明合联、恒瑞医药均大跌7%。\n编辑丨瑜见\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：孙同怀","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-06-03/doc-iniacnun2375144.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-03/doc-iniacnun2375144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000320264.USD","LU1226287529.USD","BK0060","LU0431992006.USD","LU0348827113.USD","LU0251144936.SGD","LU0831103253.SGD","LU0229945570.USD","BK1583","IE00BPRC5H50.USD","LU0314109678.HKD","IE0003795394.USD","BK1575","LU2087589342.USD","02800","LU0359201612.USD","SG9999001069.SGD","LU0880133367.SGD","07552","LU1196710864.SGD","LU2242644610.SGD","LU0345776255.USD","SG9999002463.SGD","LU0315178854.USD","LU1642822792.SGD","LU2226246903.HKD","LU2362541513.USD","03690","LU2237443465.HKD","BK4220","LU0417516738.SGD","SG9999014906.USD","LU1003077747.HKD","LU0070217475.USD","LU0738912210.USD","LU0823413587.USD","LU0823413660.USD","LU2495084118.USD","LU1951186391.HKD","IE0008369823.USD","LU0210527791.USD","03067","BK4614","LU1675838814.USD","BABO","LU0784639295.USD","LU2251237306.USD","LU0589944569.HKD","LU0972618739.USD","LU0856984785.SGD","LU0541502299.USD","LU0553294199.USD","LU1046422090.SGD","LU0469268626.HKD","BABX","LU0329678337.USD","IE00B8HQ1Z84.USD","SG9999017495.SGD","LU1064131003.USD","SG9999014914.USD","BK1141","07500","LU0384037296.USD","BK1586","LU0531970944.HKD","LU1226288170.HKD","LU1046421795.USD","BK4554","LU0918141887.USD","LU1328277881.USD","LU2237443382.USD","LU0143863784.USD","LU0149534421.HKD","LU0143863198.USD","BK1615","LU1064130708.USD","BK1526","LU0043850808.USD","IE00BQXX3D17.EUR","IE00B031J352.USD","LU0173614495.USD","LU1048588211.SGD","LU1917777945.USD","BK1095","LU2265009873.SGD","LU0648948544.HKD","LU0251143458.SGD","HK0000320223.HKD","LU0132412106.USD","LU0862451837.USD","LU0048388663.USD","LU1439102457.SGD","LU0370786039.SGD","LU0327786744.USD","LU0878005551.USD","BK1517","LU1733274390.USD","LU1267930227.SGD","LU1831875114.USD","HHImain","LU0683595622.HKD","09067","SG9999015952.SGD","LU2097828557.USD","SG9999002562.SGD","LU0163747925.USD","LU1023057109.AUD","LU1316542783.SGD","IE0003851619.USD","LU0823426480.USD","LU2476274720.SGD","GB00BDT5M118.USD","LU0456842615.SGD","IE00B0169N27.USD","LU0029874905.USD","LU2449936058.SGD","LU1282648689.USD","LU1820825898.SGD","BK1521","LU2462611646.USD","LU0594300419.USD","LU0269904917.USD","LU2177674079.SGD","MPNGY","HK0001040143.USD","LU0577902454.USD","IE0009570106.USD","LU0823038988.USD","LU0823397285.USD","SG9999015978.USD","09988","LU0890818403.SGD","LU0211977185.USD","LU0588545730.USD","LU1188198961.HKD","HK0000914660.USD","LU0828237940.HKD","LU1655091459.SGD","LU1981816686.USD","LU1235295612.USD","LU0329678170.USD","IE00B067MR52.USD","LU1718418525.SGD","SG9999007991.SGD","LU1102505929.USD","LU1769817096.USD","LU0326950275.SGD","SG9999014898.SGD","LU0786609619.USD","BK4534","LU1629966141.USD","LU0067412154.USD","LU1813983027.USD","LU1323998911.USD","LU0140636845.USD","LU0011963245.USD","SG9999001689.USD","LU0541501648.USD","LU2237443622.USD","LU0210526637.USD","BK0012","IE00B0169L03.USD","IE00BFMHRM44.USD","LU1115378108.SGD","LU1051768304.USD","SG9999001051.SGD","LU1956131251.USD","BK4504","IE00BQXX3F31.USD","LU1152091754.HKD","LU0326948709.USD","IE00BGV7N243.SGD","LU0672654166.SGD","83115","LU0865486749.SGD","LU0823040885.USD","LU0577902611.USD","LU0359202008.SGD","LU1993786604.SGD","LU0823039010.USD","03115","LU1439103000.SGD","LU2778985437.USD","MCHmain","07226","LU0348735423.USD","LU2008162690.USD","LU0348825331.USD","SGXZ51526630.SGD","LU0196878994.USD","03033","LU2294711473.HKD","BK4587","LU0348788117.USD","LU0106252389.USD","BK4505","SG9999018857.SGD","LU0128522744.USD","IE00B8L5B284.USD","KBAB","LU1282649067.USD","09618","LU0605514214.HKD","LU1807302812.USD","LU1823568750.SGD","LU1868838027.USD","LU1044875133.USD","IE00B0JY6N72.USD","LU1196710195.USD","LU0128525689.USD","LU0320764243.SGD","LU0868486357.SGD","LU0054450605.USD","LU1688375341.USD","LU0052750758.USD","LU0561508036.HKD","IE00B29SXG58.USD","LU1868837565.USD","09115","LU2362541273.HKD","IE0008368742.USD","LU0878004406.USD","LU0320764755.SGD","BK1604","LU0192582467.USD","LU0572940350.SGD","SG9999001226.SGD","LU0310800965.SGD","LU0516423091.SGD","BK0183","WXXWY","LU2399975544.HKD","LU0289960550.SGD","LU0054237671.USD","LU0080751232.USD","LU0499858438.USD","LU0307460666.USD","BK4588","LU0210533765.USD","LU0414403682.SGD","LU1719994722.HKD","LU2257852520.SGD","BK4527","LU1481107354.HKD","SG9999000327.SGD","BABA","LU0543330483.HKD","LU1997244956.HKD","LU0572939691.SGD","LU0049853897.USD","LU0456846285.SGD","LU0072462343.USD","LU0211331839.USD","IE00B031HW06.USD","LU0708995583.HKD","LU0261947096.USD","LU0169518387.USD","LU0029875118.USD","LU2237443895.HKD","02833","LU1568876251.USD","LU2051468812.USD","LU2097828714.EUR","LU0791590937.USD","02269","SG9999004220.SGD","BK4535","LU1282649810.SGD","LU0449515922.USD","BK1619","LU0640798160.USD","SG9999018865.SGD","SG9999000418.SGD","IE00B3M56506.USD","LU1048596156.SGD","IE00B031HY20.USD","LU1691799644.USD","HK0000914686.HKD","LU2476274308.USD","HK0000352291.HKD","BK1588","LU1770036033.HKD","LU1211504680.USD","LU1282651121.HKD","LU1515016050.SGD","LU0577902298.EUR","LU0048580855.USD","LU2023250504.SGD","LU0516422952.EUR","LU0918141705.HKD","LU0588546209.SGD","LU1868837722.USD","BK4524","SG9999006514.SGD","HK0000306701.USD","LU0797268264.HKD","LU1733274473.HKD","LU1568876335.HKD","BK4575","LU0572944931.SGD","LU0661504455.SGD","LU0651946864.USD","LU0345769631.USD","BK1531","LU2097828631.EUR","LU0463099449.HKD","LU0700851271.USD","LU0516423174.USD","LU0051755006.USD","LU1235294995.USD","513600","BK4538","LU0449509016.USD","LU0039217434.USD","LU0345769128.USD","LU0501845795.SGD","LU0823397103.USD","LU0791591158.USD","LU1224444064.USD","LU1146622755.USD","BK0239","LU1303224171.USD","LU0117844026.USD","LU0214875030.USD","LU0456827905.SGD","LU0107464264.USD","LU0244354667.USD","LU2362540622.SGD","LU0577902371.SGD","LU2580892789.USD","LU1804176565.USD","SG9999000459.SGD","LU0127658192.USD","LU0650527681.SGD","LU0417516902.SGD","LU0898667661.SGD","LU2148611432.USD","LU1810669033.SGD","LU0608807433.USD","IE0003895053.USD","LU0611395673.USD","LU0320764599.SGD","LU0738911758.USD","IE00B97KM107.HKD","LU0862451753.SGD","LU0737861699.HKD","LU0441854154.USD","LU0488056044.USD","LU0348783233.USD","LU2488822045.USD","03088","LU0823426308.USD","LU1969619763.USD","LU0502904849.HKD","LU0593848301.USD","LU1366334651.USD","LU1282649141.HKD","SG9999013353.USD","LU2251237488.HKD","LU2125910849.SGD","BK4531","600276","IE00BQXX3C00.GBP","BK4548","LU0540923850.HKD","BK4503","LU1883866441.USD","BABW","IE0034224299.USD","LU0128522157.USD","LU0164880469.USD","BK1591","BK1618","LU2237443978.SGD","LU1224709979.USD","HK0000151867.HKD","LU0106259558.USD","BK4607","LU1769817179.HKD","SG9999015986.USD","LU1044876610.USD","LU0545039389.USD","82800","SG9999002828.SGD","LU0348805143.USD","LU0293314216.USD","BK4526","LU0516422440.USD","LU0633140727.USD","LU1242518857.USD","LU0405327148.USD","07300","LU1226288097.SGD","09088","LU0985320562.USD","LU0165289439.USD","LU0164865239.USD","BK0188","BK4585","LU2580892862.HKD","HK0000306685.HKD","LU1781817850.SGD","LU3063872942.SGD","LU1251922891.USD","LU1725190679.HKD","LU1814569148.SGD","SG9999006597.SGD","BK4122","LU0886674414.USD","LU1997245094.SGD","SGXZ99366536.SGD","BK1502","LU0455707207.USD","LU0188438112.USD","LU0642271901.SGD","HMTD.SI","LU1974910355.USD","LU1242518931.SGD","LU0509642566.USD","03423","LU0049112450.USD","LU0819121731.USD","SG9999015945.SGD","LU0594300179.USD","HK0000352382.USD","LU0675040207.SGD","LU1226288253.USD","LU0072913022.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU2498475776.HKD","LU0873338254.USD","LU1504937902.USD","LU0203347892.USD","SG9999014674.SGD","LU0821914370.USD","LU1997245177.USD","IE0032431581.USD","LU0819123356.HKD","SG9999001846.SGD","IE00BZ08YS42.EUR","LU0181495838.USD","LU0608807946.USD","BK0028","BK4543","LU0061477393.USD","LU0577902538.SGD","LU0543330566.HKD","LU1102505762.USD","LU0396098781.USD","LU2097828805.USD","LU0405327494.USD","LU2279701549.SGD","LU1226287792.SGD","LU0828238088.HKD","LU1008478684.HKD","LU0264606111.USD","LU0052756011.USD","LU1808992512.USD","SG9999001903.USD","LU0633140560.USD","LU1328615791.USD","LU0328353924.USD","LU2045819591.USD","LU0175139822.USD","BK1249","LU0588545490.SGD","TCEHY","LU2247934214.USD","LU1655091616.SGD","IE0031814852.USD","LU2125910500.SGD","IE00BZ08YR35.GBP","LU0254981946.USD","LU2039709279.SGD","BK1589","LU0096374516.USD","LU0588545904.SGD","LU0882747503.HKD","IE0001KFT4U8.USD","IE0008368411.USD","LU0106959298.USD","LU1880383440.USD","LU0231483743.USD","LU0203345920.USD","IE00B543WZ88.USD","00700","LU2148510915.USD","LU0348723411.USD","LU1880383366.USD","LU1226287875.USD","LU1255011170.USD","01276","HTCD.SI","LU0499858602.USD","LU1794554557.SGD","IE00BF5LJ272.USD","LU1785774172.SGD","LU1770034418.SGD","BK4581","LU2152927971.USD","BBYY","LU1734074674.USD","LU0348816934.USD","LU0979878070.USD","03037","LU2289578879.USD","LU2328871848.SGD","SG9999003461.SGD","LU2317271919.USD","LU0828237510.HKD","LU0047713382.USD","LU0871576103.HKD","LU0149721374.USD","LU1196710351.USD","BK1142","LU0084288322.USD","LU0287142896.SGD","03032","LU1048484197.HKD","SG9999001093.SGD","LU1152091168.USD","LU0516422366.SGD","SG9999014880.SGD","LU0531971595.HKD","LU0348783662.USD","LU0737861772.HKD","BK4502","BK1516","LU0261950983.USD","SGXZ31699556.SGD","IE00BZ08YT58.USD","LU2106854487.HKD","BK4558","LU0259732245.USD","LU1580142542.USD","LU0228659784.USD","LU0228367735.SGD","LU2097828474.EUR","LU1044874839.SGD","LU2293587155.HKD","LU2133065610.SGD","89618","BK4533","LU0708995153.HKD","LU0345775950.USD","LU0823041008.USD","LU0117841782.USD","LU0315179316.USD","LU1105468828.SGD","LU0235996351.USD","BK0196","LU0651947912.USD","BK1576","07200","LU1960683339.HKD","BK1608","HSI","JD","LU2237443549.SGD","MHImain","LU0164872284.USD","LU1366334578.USD","BK4565","LU0348814723.USD","LU0048597586.USD","LU0348784397.USD","HK0001040168.HKD","LU0417516571.SGD","LU1051769294.HKD","LU1282651048.USD","LU0949170772.SGD","IE0032834883.USD","03417","02837","LU0359201885.HKD","03419","SGXZ81514606.USD","LU1720050803.USD","LU0607220059.USD","SGXZ90724238.SGD","BK4579","BK1609","LU1961090484.USD","BK1610","BABU","BK1233","HSTECH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640491601","title":"恒瑞医药(01276)：截至5月末公司累计回购A股股份1205.62万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640491601","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640491601?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:13","pubTimestamp":1780391596,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，2026年5月，公司通过上海证券交易所交易系统以集中竞价交易方式回购股份0股。截至2026年5月31日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份1,205.62万股，已回购股份占公司总股本的比例为0.18%，购买的最高价为人民币70.00元/股，最低价为人民币53.52元/股，已支付的总金额为人民币77,198.09万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","LU1997245094.SGD","BK0239","LU2289578879.USD","LU1820825898.SGD","LU2097828805.USD","LU2580892789.USD","BK0188","LU1997245177.USD","01276","LU0359201612.USD","LU2495084118.USD","BK0183","LU2097828557.USD","159982","LU1328615791.USD","BK1191","LU1023057109.AUD","LU1580142542.USD","600276","LU2097828474.EUR","LU1064131003.USD","LU2543165471.USD","LU0405327494.USD","LU2097828631.EUR","LU1997244956.HKD","399300","LU1146622755.USD","BK0196","LU0405327148.USD","BK0028","BK0060","LU1969619763.USD","LU2328871848.SGD","BK0012","LU2097828714.EUR","LU0359201885.HKD","LU0359202008.SGD","LU2580892862.HKD","LU1781817850.SGD","LU2488822045.USD","LU2148510915.USD","LU1655091616.SGD","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640167049","title":"恒瑞医药累计回购1206万股 金额7.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640167049","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640167049?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:07","pubTimestamp":1780391220,"startTime":"0","endTime":"0","summary":"6月2日，恒瑞医药（600276/01276）发布公告，截至2026年5月31日，公司已回购1206万股，占总股本的0.18%，累计回购金额为7.72亿元，回购价格区间为53.52元/股至70元/股。2026年一季度，恒瑞医药实现收入81.41亿元，归母净利润22.82亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606023757608896.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828631.EUR","600276","LU1064130708.USD","LU2328871848.SGD","LU1064131003.USD","LU0359202008.SGD","LU0405327494.USD","LU2543165471.USD","LU1655091616.SGD","LU1997244956.HKD","LU2495084118.USD","LU1580142542.USD","BK0196","LU2097828557.USD","LU2097828714.EUR","LU1146622755.USD","LU1328615791.USD","LU2148510915.USD","BK0183","BK0239","BK0028","LU0359201612.USD","LU2580892789.USD","LU1820825898.SGD","BK0188","LU1255011170.USD","BK1191","LU2097828474.EUR","BK0060","BK0012","LU2289578879.USD","LU1969619763.USD","LU1023057109.AUD","LU0359201885.HKD","LU2488822045.USD","01276","LU0405327148.USD","LU1997245094.SGD","LU1781817850.SGD","LU2097828805.USD","LU1997245177.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640317951","title":"恒瑞医药：公司坚持科技创新与国际化发展战略，致力于发展好主营业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2640317951","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640317951?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:01","pubTimestamp":1780315260,"startTime":"0","endTime":"0","summary":"证券日报网讯6月1日，恒瑞医药在互动平台回答投资者提问时表示，二级市场股价波动受多种因素影响，公司日常经营管理和业务状况正常。公司坚持科技创新与国际化发展战略，致力于发展好主营业务，促进公司业绩可持续增长，以更好的发展回馈股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013756213975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1781817850.SGD","LU2488822045.USD","600276","LU1255011170.USD","BK0028","LU2097828557.USD","LU1064131003.USD","BK0196","LU1580142542.USD","LU0405327148.USD","LU2495084118.USD","LU1328615791.USD","BK1191","LU2097828805.USD","BK0183","LU2328871848.SGD","LU2148510915.USD","LU1655091616.SGD","LU2543165471.USD","LU0405327494.USD","LU1997245094.SGD","LU2097828631.EUR","LU0359202008.SGD","BK0060","LU2097828474.EUR","LU0359201612.USD","BK0012","LU1023057109.AUD","LU1997245177.USD","LU1064130708.USD","BK0188","LU2580892789.USD","LU1146622755.USD","LU1820825898.SGD","01276","LU2580892862.HKD","LU1969619763.USD","LU1997244956.HKD","LU0359201885.HKD","BK0239","LU2097828714.EUR","LU2289578879.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676739","title":"恒瑞医药：公司将继续大力推进“科技创新”和“国际化”两大发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676739","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676739?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:59","pubTimestamp":1780066740,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，公司将继续大力推进“科技创新”和“国际化”两大发展战略，稳步推进研发创新和制剂产品的国际化。同时，也将着力于产品结构的优化提升，通过产品创新升级和多元化产品管线的拓展推动公司的持续发展，促进公司业绩可持续增长，以更好的发展回馈股东。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754793698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201612.USD","LU1997245177.USD","LU1655091616.SGD","LU2097828631.EUR","BK0196","LU2495084118.USD","BK0060","LU2097828557.USD","LU1064130708.USD","LU1328615791.USD","BK0188","LU2289578879.USD","BK1191","LU1820825898.SGD","LU2580892789.USD","LU2580892862.HKD","LU1023057109.AUD","LU2097828474.EUR","LU1997244956.HKD","LU2488822045.USD","LU2543165471.USD","LU0359201885.HKD","LU2097828805.USD","LU1255011170.USD","600276","LU1781817850.SGD","LU1064131003.USD","LU1580142542.USD","BK0183","LU2328871848.SGD","BK0239","BK0012","LU0405327494.USD","LU1146622755.USD","LU1997245094.SGD","LU2097828714.EUR","LU2148510915.USD","01276","LU1969619763.USD","LU0359202008.SGD","LU0405327148.USD","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676731","title":"恒瑞医药：公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676731","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676731?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:58","pubTimestamp":1780066680,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，为保障2025年年度权益分派方案实施，公司本轮回购工作自权益分派实施筹备工作启动之日至权益分派实施完毕期间暂停。公司本轮回购期限为自2025年8月20日董事会审议通过回购股份方案之日起12个月以内，目前本次回购尚未结束。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754790498.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","LU1997244956.HKD","LU2580892789.USD","LU1969619763.USD","LU2495084118.USD","LU2488822045.USD","LU1064131003.USD","LU0405327494.USD","LU1255011170.USD","LU2097828631.EUR","LU2148510915.USD","LU2097828474.EUR","LU1997245177.USD","LU2543165471.USD","LU1580142542.USD","BK0012","LU2097828557.USD","600276","LU1781817850.SGD","BK0188","LU2097828805.USD","BK0060","LU0359201885.HKD","LU2289578879.USD","LU0405327148.USD","LU1146622755.USD","LU1655091616.SGD","LU1820825898.SGD","BK0239","LU1023057109.AUD","LU2328871848.SGD","LU0359201612.USD","BK0028","LU1328615791.USD","LU2097828714.EUR","BK0183","LU2580892862.HKD","01276","BK0196","LU0359202008.SGD","BK1191","LU1997245094.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639676986","title":"恒瑞医药：公司目前已在中国获批上市25款1类创新药、5款2类新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2639676986","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639676986?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:48","pubTimestamp":1780066080,"startTime":"0","endTime":"0","summary":"证券日报网讯5月29日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持科技创新战略，目前已在中国获批上市25款1类创新药、5款2类新药，另有100多个自主创新产品正在临床开发，400余项临床试验在国内外开展。经营业绩方面，创新成果转化高效赋能，创新药销售引领业绩增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754780227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1655091616.SGD","LU0359201885.HKD","LU1064130708.USD","LU1328615791.USD","600276","BK0188","LU2148510915.USD","BK0239","BK0028","LU2097828474.EUR","LU1580142542.USD","LU1997244956.HKD","LU2488822045.USD","LU2495084118.USD","LU2097828714.EUR","LU2289578879.USD","LU1064131003.USD","06978","LU1781817850.SGD","LU2580892789.USD","LU1820825898.SGD","BK0060","LU0405327494.USD","BK1191","BK1161","LU0359202008.SGD","159992","LU2097828557.USD","LU1997245177.USD","BK0196","LU1969619763.USD","LU2543165471.USD","01276","LU0359201612.USD","LU2580892862.HKD","LU1023057109.AUD","LU1255011170.USD","LU2097828631.EUR","LU1997245094.SGD","BK0012","LU2328871848.SGD","IPOS","BK1574","LU2097828805.USD","LU0405327148.USD","BK0183","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782048841605,"stockEarnings":[{"period":"1week","weight":0.0307},{"period":"1month","weight":-0.0576},{"period":"3month","weight":-0.1183},{"period":"6month","weight":-0.201},{"period":"1year","weight":-0.0616},{"period":"ytd","weight":-0.1838}],"compareEarnings":[{"period":"1week","weight":0.026},{"period":"1month","weight":-0.019},{"period":"3month","weight":0.0337},{"period":"6month","weight":0.0514},{"period":"1year","weight":0.2071},{"period":"ytd","weight":0.0306}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"458309人(较上一季度增加1.93%)","perCapita":"13918股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}